Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non-Current Liabilities (2016 - 2025)

Ligand Pharmaceuticals' Other Non-Current Liabilities history spans 16 years, with the latest figure at $19.9 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 33.35% year-over-year to $19.9 million; the TTM value through Sep 2025 reached $19.9 million, down 33.35%, while the annual FY2024 figure was $30.2 million, 8.66% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $19.9 million at Ligand Pharmaceuticals, up from $14.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $43.7 million in Q3 2023 and bottomed at $14.2 million in Q1 2025.
  • The 5-year median for Other Non-Current Liabilities is $27.8 million (2022), against an average of $26.0 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 98.96% in 2023 before it plummeted 51.04% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $29.6 million in 2021, then dropped by 6.06% to $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then rose by 8.66% to $30.2 million in 2024, then crashed by 33.99% to $19.9 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Non-Current Liabilities are $19.9 million (Q3 2025), $14.4 million (Q2 2025), and $14.2 million (Q1 2025).